Valescia John

Current Location: Upper Darby, PA

Summary:
 Highly analytical, scientific and clinical expert with success managing research projects, leading therapeutic studies
(phase I to III), and supporting end-to-end development of pharmaceutical products.
 Extensive expertise in epidemiology, biostatistics, pharmacology, rare diseases, and disease surveillance. In-depth
knowledge of GCP, GMP, and GLP with proven ability to plan, organize and manage resources to ensure completion
of specific study/project goals and objectives in accordance with defined quality and time-based metrics.
 Credible history of analyzing and sub-culturing more than hundred samples on daily basis, while documenting results
and generating/delivering reports to customers and state agencies.
 Instrumental at overseeing preparation of scientifically valid publications by identifying key topics, defining sources
of data, reviewing data analysis plans, writing manuscripts, developing posters/oral presentations and graphic
displays.
 Earned reputation as an inspirational leader and coach with history of leading, training, and guiding teams and
learners on scientific/research methodologies, environmental health principles, and epidemiology.
 Strong written and verbal communication skills with an ability to thrive in a fast-paced environment, while staying
current with rapidly evolving technologies.

Skills:
 Clinical Research
 GMP/GCP/GLP
 Drug Safety & Development
 FDA & EPA Regulations
 Disease Surveillance
 Project Management
 Strategic Planning
 Scientific/Technical Writing
 SOPs Development
 Coaching & Mentoring
 Scientific Affairs Management
 Therapeutic Studies
 Quality Assurance & Testing
 Technical Resource Management
 Staff Training & Leadership

Technical Proficiencies:
 SPSS
 STATA
 MS-Office
 Adobe Photoshop
 SoftMax
 Therapeutic Areas: Oncology, Inflammation, Immunology, Dermatology, CNS, Gastroenterology
 Research Areas: Maternal & Child Health, Pediatric Health Disparities, Behavioral & Mental Dysfunction
 GMP, GLP, GCP, ICH guidelines EDMS, Documentum, LIMS, Records Management, Compliance FDA & EPA
regulations, CFR SOPs, IRB submission

Additional Experience:
 Family Services Network of New York, Inc., Brooklyn, NY
 HIV Prevention Educator/Outreach Coordinator, Comrades in A.R.M.S. (CIA), 2012
 Program Assistant & Data Analyst, Comrades in A.R.M.S. (CIA), 2012
 Harm Reduction/Ryan White Mental Health Program, 2011-2012
 Clinproxy Research Services, Henderson, NV
 Clinical Research Associate, Clinical Trial Monitoring & Research Site Coordination, 2009-2010
Publications:
 Holmes L Jr, Enwere M, Williams J, Ogundele B, Chavan P, Piccoli T, Chinacherem C, Comeaux C, Pelaez L,
Okundaye O, Stalnaker L, Kalle F, Deepika K, Philipcien G, Poleon M, Ogungbade G, Elmi H, John V, & Dabney
KW. Black-White Risk Differentials in COVID-19 (SARS-COV2) Transmission, Mortality and Case Fatality in the
United States: Translational Epidemiologic Perspective and Challenges. Int J Environ Res Public Health. 2020;17
(12):4322. Published 2020 Jun 17. doi:10.3390/ijerph17124322
 Holmes LJ, Stalnaker L, Casini J, Morgan I, John V, Dabney K. Childhood Autism Spectrum Disorder and Epilepsy
Cooccurrence: Sub-population Prevalence Variances and Risk Modelling. Epidemiology Journal. 2017; 3(2):119. doi:
10.4172/2472-0895.1000119
 VX John, BN Willems, KW Dabney, P Oceanic, L Holmes, Jr. Childhood Behavioral and Mental Dysfunction
Prevalence. Research Centers in Minority Institutions (RCMI) Translational Science Conference, Abstract
#02.01.021, October 2017.
 VX John, C Thompson, AR Wallace, P Oceanic, G Datto, T Phan, KW Dabney, L Holmes, Jr. Food Insecurity &
Health Outcomes Among Children. Research Centers in Minority Institutions Translational Science Conference,
Abstract #03.01.054, Oct 2017.
 John, VX, Sur, R, Mariano, TM, Heck, DE, and Laskin, JD. UVB Light Induces Degradation of Cyclooxygenase-2
(COX-2) mRNA. The Toxicologist, Vol. 66, No. 1-S, Abstract #LB84, pg. 23, March 2002.John, VX, Laskin, JD, and
Heck, DE. Regulation of COX-2 Expression in Human Dermal Microvascular Epithelial Cells by 2, 3, 7, 8-
Tetrachlorodibenzo-p-Dioxin (TCDD). The Toxicologist, Vol. 60, No. 1, Abstract #2099, pg.441, March 2001.

Education:
 Walden University, Minneapolis, MN
PhD, Public Health (Epidemiology)
 Kriger Research Group International, Huntsville, Ontario
Clinical Research Associate (CRA)
 Rutgers University, New Brunswick, NJ
MS in Toxicology and Pharmacology
 Oakwood University, Huntsville, AL
BS in Chemistry (Major) and Mathematics (Minor)

Professional Experience
Oakwood University, Huntsville, AL 2019 to Present
Adjunct Professor, Masters of Public Health Program & LEAP Adult Degree Completion Program
 Teach two courses (Principles of Environmental Health and Health Principles) to graduate students during Fall and
Spring.
 Support students in understanding ecological and ecosystem's impact on public health, epidemiological importance to
risk assessment, and effect of regulatory toxicology on public health policy. Prepare learners to analyze and address
specific
 environmental threats, such as toxic metals, radiation, pesticides, outdoor and indoor pollutants that cause multiple
diseases (including cancer, heart disease, asthma, and impaired child development).
 Health Principles Course - Improved students’ awareness about the principles of healthful living that involved a study
of the fundamental physiological processes.
 Principles of Environmental Health Course - Enhanced skillset of students on environmental health and spatial scales
(from local to global) through effective training and guidance.
 Maintained a class environment that provided freedom of thought and debate, informing students of Christian values
and choices that reflected the University’s mission.
 Received positive feedback from learners – 100% of students thought that delivered-instructions are relevant to
subject and following course goals.

CHDI Management, Inc., Princeton, NJ 2018 to 2020

Director, Biomedical Studies Clinical Research
 Facilitated with the execution of clinical research projects through robust planning and cross-functional collaboration.
 Project 1 (Enroll-HD—large scale Huntington’s Disease participant registry; HDClarity; HD-Yas; HD-Registry):
Managed overall project activities, including processing of payment invoices.
 Project 2 (Origin-HD—semen collection study): Leveraged strong clinical acumen to deliver consultancy for
successful execution of the research project.
 Project 3 (selfEnroll-HD digital registry platform to enhance Enroll-HD): Drafted project synopsis/protocol to provide
a panoramic view of research for quick analysis by the reviewers. Prepared documents for submission to the
Institutional Review Board (IRB) aimed at acquiring ethical clearance of the research methods.\
 Project 4 (iMarkHD PET imaging study): Ensured quality control for database creation by reviewing electronic data
capture (EDC) specifications. Launched participant enrollment for study initiation, as a key member of management
team.
 Project 5 (Biomarker Development Research Project): Played a key role in starting research project through gainful
contract negotiations. Allocated resources for initiation of biomarker project by overseeing development of
appropriate documents. Maintained consistent engagement with senior management to update about project’s
progress.

Nemours/Alfred I. DuPont Hospital for Children, Wilmington, DE 2017

Epidemiology Doctoral Fellow
 Coordinated 40 hours of a study on autism/epilepsy co-occurrence prevalence and risk markers with a national data
(National Survey of Children’s Health, 2012). Gained in-depth knowledge of pediatric health disparities by
collaborating with fellows working three research projects of similar field.
 Organized eight weeks of journal club for undergraduates, while presenting two original research topics at public
health conferences.
 Mentored nine undergraduates on five topics in statistics (STATA), four epidemiology topics, and three public health
topics.

City of Philadelphia, Water Department, Philadelphia, PA 2014 to 2017

Environmental Scientist / Science Technician
 Examined the ecological effects of pollutants by gathering data for environmental impact studies. Analyzed and
transformed data into meaningful information by conducting statistical analyses using created/standardized solutions
and reagents, while maintaining and monitoring data records and laboratory equipment. Documented and maintained
results as per laboratory manual and state/federal regulations for future usage.
 Analyzed ~60 samples daily as per state/federal EPA regulations (from various sites around the city of Philadelphia).
 Oversaw biological aspects of Human Tracer Study in collaboration with local university.
 Enhanced competency of six students on routine laboratory methods through regular training.
 Ensured validity and optimal functionality of instrumentation through regular evaluation and recalibration.

Sure-Biochem Laboratories, LLC., Camden, NJ 2013 to 2014

Microbiology Laboratory Manager
 Ensured customer accreditation/quality assurance based on federal and state regulations by conducting environmental
monitoring at 3 external sites. Facilitated supervisor with collection of appropriate documents for grant and contract
proposal submissions.
 Analyzed, read, and sub-cultured more than 100 samples on daily basis, while documenting results and
generating/delivering reports to customers and state agencies.
 Delivered effective coaching to employees and interns on existing microbiological methods and company policies.

Centocor, Inc. (Johnson & Johnson), Radnor, PA / Raritan, NJ 2003 to 2010

Associate Scientist, Bioassay Method Development / Assistant Scientist, Protein Purification
 Evaluated quality of drug products under the influence of a variety of environmental factors by carrying out release
and stability testing. Assessed the suitability of products for market positioning by conducting various bioassay and
Enzyme
 Immuno Assay (EIA)/Enzyme-linked Immunosorbent Assay (ELISA) methods (Protein A, Host Cell Protein (HCP),
Residual DNA/qPCR). Authored SOPs, created technical documents, and qualified EIA/ELISA methods for all
products.
 Maintained five cell lines for bioassay methods as well as developed antibody and HCP EIA as an entry level
scientist.
 Studied therapeutic agents that were later transformed into marketable drugs, including STELARA®, REMICADE®,
SIMPONI®.
 Successfully drove five projects from conception to completion by utilizing effective research methodologies and
pharmaceutical industry knowledge.
 Improved operational efficiency by leading and training new associate of multiple bioassay and EIA/ELISA methods.
 Analyzed a recombinant protein product by utilizing protein purification techniques:
 Prevented leaching into drug causing potential patient harm by optimizing storage methods for recombinant protein
product.
 Executed Native and SDS-PAGE, Gel Densitometry, Fluorescence, UV/Vis Spectroscopy, SEC-HPLC, TLC, SPE to
analyze impurities of storage methods for recombinant protein product.
 Fostered collaboration across multiple departments through active participation in Bridges rotational program.